Ozempic and other GLP-1 drugs may slow biological aging

Background

Medications such as Ozempic, Wegovy, Mounjaro and Zepbound are known for weight loss and glucose control. Recent studies suggest they might also affect biological aging.

What do aging clocks measure?

Manufacturers presented data at the 13th Aging Research & Drug Discovery conference. The Novo Nordisk team analyzed existing clinical trials to see how semaglutide influenced molecular aging markers, called aging clocks.

• Clocks use biological changes to estimate aging rather than chronological age.
• Semaglutide users showed reductions in these markers compared to placebo.
• Effect size varied by clock and organ, generally 2–3 years, up to 4 years for a heart‑protein clock.

Tirzepatide also shows favorable results

Eli Lilly researchers performed a similar analysis with tirzepatide, the active ingredient in Mounjaro and Zepbound. The drug targets GLP‑1 and GIP pathways.

• Epigenetic clocks indicated slower aging in users versus controls.
• All clocks pointed in the same direction, but no reversal of decades was claimed.

Limitations and next steps

Studies have not undergone peer review and were conducted by the manufacturers. Independent research is needed to confirm findings.

• Participants were obese or type‑2 diabetic; results may not apply to healthy individuals.
• It remains unclear how improvements in clocks translate to real health benefits.
• Animal studies hint at increased lifespan, but human data are lacking.
• Upcoming federal trials will test whether GLP‑1 drugs extend life and promote healthy aging in people over 60.

For now, the data provide a promising clue. The decisive question is whether changes in molecular clocks correspond to longer, healthier lives—a question these analyses cannot yet answer.